In support of this strategy, the administration of CD47-specific mAb inhibited in vivo the growth of xenografted tumors developed from patient-derived lung cancer cells or cancer stem cells by recruiting macrophages into the tumor microenvironment (49). Here, CD47 is linked to lung carcinoma.